The Allergy / Immunology Channel

Mepolizumab Fails in a Phase II Trial

Fails to alleviate moderate persistent asthma symptoms

1:06 | Allergy / Immunology, Family Medicine, Internal Medicine, Pharmacists, Preventative Health, Pulmonary Medicine

Mepolizumab, an IL-5 inhibitor, failed to alleviate moderate persistent asthma symptoms in a phase II trial of patients resistant to corticosteroids.

References and Resources
Flood-Page P, Swenson C, Faiferman I. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. American Journal of Respiratory and Critical Care Medicine. 2007. Vol 176; pp. 1062-1071.

Click Here to view abstract.

More in Allergy / Immunology

► 1:59

Immunological Mechanism Defense Against COPD Pathogens

Allergy / Immunology

Results from a study led by Daniel Enosi Tuipulotu, BSc, a postdoctoral fellow at the John Curtin School of Medical Research, Australian National University, Canberra, demonstrated that Moraxella catarrhalis, a...

► 1:18:26

CDC Advisory Committee on Immunization Practices: Influenza 2022-2023

Allergy / Immunology

In a meeting of the Advisory Committee on Immunization Practices in March 2023, the focus was on the respiratory disease surge in Fall 2022 in the United States, with presentations...

► 5:43:30

FDA VRBPAC Meeting: RSV Treatment

Allergy / Immunology

The focus of the 179th Meeting of Vaccines and Related Biological Products Advisory Committee was on the biologics license application for respiratory syncytial virus (RSV) vaccine recombinant, Adjuvanted (AREXVY). Experts...

► 28:43

Viral Therapy & Immunotherapy

Allergy / Immunology

Rimas V. Lukas, MD, associate chief, neuro-oncology division, Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, discusses current and emerging research on the use of immunotherapy and oncolytic viruses for...